KRAS and pancreatic ductal adenocarcinoma: This retrospective analysis of patients with metastatic and locally advanced pancreatic ductal adenocarcinoma characterizes prognostic or predictive genomic markers for this patient population, with a focus on KRAS mutational variants and their interaction with concurrent molecular alterations.